(Q45040972)

8 December 2017

title

Pharmacokinetics of dextromethorphan after single or multiple dosing in combination with quinidine in extensive and poor metabolizers (English)

1 reference

8 December 2017

1 reference

6

1 reference

8 December 2017

Laura E Pope

1

1 reference

8 December 2017

M H Khalil

2

1 reference

8 December 2017

James E Berg

3

1 reference

8 December 2017

Mark Stiles

4

1 reference

8 December 2017

Gerald J Yakatan

5

1 reference

8 December 2017

publication date

1 October 2004

1 reference

The Journal of Clinical Pharmacology

8 December 2017

published in

1 reference

8 December 2017

volume

44

1 reference

8 December 2017

issue

10

1 reference

8 December 2017

page(s)

1132-1142

1 reference

Dextromethorphan: enhancing its systemic availability by way of low-dose quinidine-mediated inhibition of cytochrome P4502D6.

8 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F0091270004269521

Neuroprotection by NMDA receptor antagonists in a variety of neuropathologies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004269521

Metabolism to dextrorphan is not essential for dextromethorphan's anticonvulsant activity against kainate in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004269521

Dextromethorphan and dextrorphan as calcium channel antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004269521

Dextromethorphan blocks N-methyl-D-aspartate-induced currents and voltage-operated inward currents in cultured cortical neurons.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004269521

Antiparkinsonian and antidyskinetic activity of drugs targeting central glutamatergic mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004269521

Dextromethorphan for the treatment of neuropathic pain: a double-blind randomised controlled crossover trial with integral n-of-1 design

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004269521

Diabetic neuropathy: pathogenesis and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004269521

The role of dextromethorphan in pain control

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004269521

Dextromethorphan and memantine in painful diabetic neuropathy and postherpetic neuralgia: efficacy and dose-response trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004269521

Analgesic effects of dextromethorphan and morphine in patients with chronic pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004269521

Dextromethorphan for phantom pain attenuation in cancer amputees: a double-blind crossover trial involving three patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004269521

NMDA-receptor antagonists in neuropathic pain: experimental methods to clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004269521

The estimation of solubility in binary solvents: application of the reduced 3-suffix solubility equation to ethanol-water mixtures.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004269521

Dose escalation safety and tolerance study of the N-methyl-D-aspartate antagonist dextromethorphan in neurosurgery patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004269521

Comparison of three CYP2D6 probe substrates and genotype in Ghanaians, Chinese and Caucasians

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004269521

Quinidine: potent inhibition of sparteine and debrisoquine oxidation in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004269521

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004269521

The antitussive effect of dextromethorphan in relation to CYP2D6 activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004269521

The influence of CYP2D6 polymorphism and quinidine on the disposition and antitussive effect of dextromethorphan in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004269521

Pharmacokinetics of dextromethorphan and metabolites in humans: influence of the CYP2D6 phenotype and quinidine inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004269521

Clinical trials of agents that reverse multidrug resistance. A literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004269521

The effect of grapefruit juice and seville orange juice on the pharmacokinetics of dextromethorphan: the role of gut CYP3A and P-glycoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004269521

Inhibition of P-glycoprotein-mediated drug transport: A unifying mechanism to explain the interaction between digoxin and quinidine [seecomments]

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004269521

Increased drug delivery to the brain by P-glycoprotein inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004269521

Psychotropic effects of dextromethorphan are altered by the CYP2D6 polymorphism: a pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004269521

Quinidine pharmacokinetics in patients with cirrhosis or receiving propranolol

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004269521

21 January 2018

Identifiers

DOI

10.1177/0091270004269521

1 reference

8 December 2017

1 reference